Aberrant insulin signaling in Alzheimer's disease: current knowledge
Open accessThe DOI matches its Crossref record; 145 of the 145 references it cites were found in a registry or an index.
Abstract
Alzheimer's disease (AD) is the most common form of dementia affecting elderly people. AD is a multifaceted pathology characterized by accumulation of extracellular neuritic plaques, intracellular neurofibrillary tangles (NFTs) and neuronal loss mainly in the cortex and hippocampus. AD etiology appears to be linked to a multitude of mechanisms that have not been yet completely elucidated. For long time, it was considered that insulin signaling has only peripheral actions but now it is widely accepted that insulin has neuromodulatory actions in the brain. Insulin signaling is involved in numerous brain functions including cognition and memory that are impaired in AD. Recent studies suggest that AD may be linked to brain insulin resistance and patients with diabetes have an increased risk of developing AD compared to healthy individuals. Indeed insulin resistance, increased inflammation and impaired metabolism are key pathological features of both AD and diabetes. However, the precise mechanisms involved in the development of AD in patients with diabetes are not yet fully understood. In this review we will discuss the role played by aberrant brain insulin signaling in AD. In detail, we will focus on the role of insulin signaling in the deposition of neuritic plaques and intracellular NFTs. Considering that insulin mitigates beta-amyloid deposition and phosphorylation of tau, pharmacological strategies restoring brain insulin signaling, such as intranasal delivery of insulin, could have significant therapeutic potential in AD treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cell Signaling by Receptor Tyrosine Kinases
Lemmon, M. A., & Schlessinger, J. (2010) · Cell · doi:10.1016/j.cell.2010.06.011 · Cited by 7,929
Querfurth, H. W., & LaFerla, F. M. (2010) · New England Journal of Medicine · doi:10.1056/nejmra0909142 · Cited by 4,569
Cell Signaling by Receptor Tyrosine Kinases
Schlessinger, J. (2000) · Cell · doi:10.1016/s0092-8674(00)00114-8 · Cited by 3,774 · cited 2×
“…metabolism leading to increased oxidative stress, inflammation, and worsening of insulin resistance (Hoyer, 2002, 2004; Schubert et al., 2004; Rivera et al., 2005; Steen et al., 2005; Watson and Craft, 2006; Craft, 2007; Neumann et al., 2008; Krikorian et al., 2010; Luchsinger, 2010; Baker…”
BackgroundNitric oxide: an endogenous modulator of leukocyte adhesion.
Kubes, P., Suzuki, M., & Granger, D. N. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.11.4651 · Cited by 3,029
Neurovascular pathways to neurodegeneration in Alzheimer’s disease and other disorders
Zlokovic, B. V. (2011) · Nature Reviews Neuroscience · doi:10.1038/nrn3114 · Cited by 2,969
Synapse loss in frontal cortex biopsies in Alzheimer's disease: Correlation with cognitive severity
DeKosky, S. T., & Scheff, S. W. (1990) · Annals of Neurology · doi:10.1002/ana.410270502 · Cited by 2,376 · cited 1×
“The neurodegeneration in AD is characterized by neuronal loss and synaptic injury (Dekosky and Scheff, 1990).”
BackgroundTalbot, K., Wang, H.-Y., Kazi, H., Han, L.-Y., Bakshi, K. P., Stucky, A., Fuino, R. L., Kawaguchi, K. R., Samoyedny, A. J., Wilson, R. S., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci59903 · Cited by 1,871 · cited 8×
“…of insulin resistance (Hoyer, 2002, 2004; Schubert et al., 2004; Rivera et al., 2005; Steen et al., 2005; Watson and Craft, 2006; Craft, 2007; Neumann et al., 2008; Krikorian et al., 2010; Luchsinger, 2010; Baker et al., 2011; Talbot et al., 2012; Butterfield et al., 2014a,b; de La Monte, 2014).”
BackgroundInfluentialSteen, E., Terry, B. M., J. Rivera, E., Cannon, J. L., Neely, T. R., Tavares, R., Xu, X. J., Wands, J. R., & de la Monte, S. M. (2005) · Journal of Alzheimer's Disease · doi:10.3233/jad-2005-7107 · Cited by 1,703
Nitric oxide directly activates calcium-dependent potassium channels in vascular smooth muscle
Bolotina, V. M., Najibi, S., Palacino, J. J., Pagano, P. J., & Cohen, R. A. (1994) · Nature · doi:10.1038/368850a0 · Cited by 1,691
Regulation of NMDA receptor trafficking by amyloid-β
Snyder, E. M., Nong, Y., Almeida, C. G., Paul, S., Moran, T., Choi, E. Y., Nairn, A. C., Salter, M. W., Lombroso, P. J., Gouras, G. K., et al. (2005) · Nature Neuroscience · doi:10.1038/nn1503 · Cited by 1,561 · cited 3×
“In the following section we will discuss the evidence of relation of insulin signaling deficiency with AD pathology and disease progression.”
BackgroundResultSniffing neuropeptides: A transnasal approach to the human brain
Born, J., Lange, T., Kern, W., McGregor, G. P., Bickel, U., & Fehm, H. L. (2002) · Nature Neuroscience · doi:10.1038/nn0602-849 · Cited by 1,356
Farris, W., Mansourian, S., Chang, Y., Lindsley, L., Eckman, E. A., Frosch, M. P., Eckman, C. B., Tanzi, R. E., Selkoe, D. J., & Guénette, S. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0230450100 · Cited by 1,286
Craft, S. (2012) · Archives of Neurology · doi:10.1001/archneurol.2011.233 · Cited by 1,253
GSK-3α regulates production of Alzheimer's disease amyloid-β peptides
Phiel, C. J., Wilson, C. A., Lee, V. M.-Y., & Klein, P. S. (2003) · Nature · doi:10.1038/nature01640 · Cited by 1,196
Lacor, P. N., Buniel, M. C., Furlow, P. W., Sanz Clemente, A., Velasco, P. T., Wood, M., Viola, K. L., & Klein, W. L. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.3501-06.2007 · Cited by 1,188 · cited 2×
“…Aβ oligomers further worsen insulin deficiency by decreasing insulin’s binding affinity to its receptors, reducing and desensitizing cell surface IRs and phosphorylating IRS-1 (Figure 1) (Lacor et al., 2007; Zhao et al., 2008;Ma et al., 2009; Fernandez and Torres-Aleman, 2012; Talbot et al., 2012).”
BackgroundResultCusi, K., Maezono, K., Osman, A., Pendergrass, M., Patti, M. E., Pratipanawatr, T., DeFronzo, R. A., Kahn, C. R., & Mandarino, L. J. (2000) · Journal of Clinical Investigation · doi:10.1172/jci7535 · Cited by 1,139 · cited 2×
“In insulin resistant state, there is a specific impairment in the vasodilatory PI3K pathway, whereas the Ras/MAPK-dependent pathway is unaffected (Jiang et al., 1999; Cusi et al., 2000).”
BackgroundCellular actions of beta-amyloid precursor protein and its soluble and fibrillogenic derivatives
Mattson, M. P. (1997) · Physiological Reviews · doi:10.1152/physrev.1997.77.4.1081 · Cited by 1,006 · cited 3×
“In the following section we will discuss the evidence of relation of insulin signaling deficiency with AD pathology and disease progression.”
BackgroundLe Roith, D. (1997) · New England Journal of Medicine · doi:10.1056/nejm199702273360907 · Cited by 897
The many faces of insulin-like peptide signalling in the brain
Fernandez, A. M., & Torres-Alemán, I. (2012) · Nature reviews. Neuroscience · doi:10.1038/nrn3209 · Cited by 872 · cited 1×
“…Aβ oligomers further worsen insulin deficiency by decreasing insulin’s binding affinity to its receptors, reducing and desensitizing cell surface IRs and phosphorylating IRS-1 (Figure 1) (Lacor et al., 2007; Zhao et al., 2008;Ma et al., 2009; Fernandez and Torres-Aleman, 2012; Talbot et al., 2012).”
BackgroundBomfim, T. R., Forny-Germano, L., Sathler, L. B., Brito-Moreira, J., Houzel, J.-C., Decker, H., Silverman, M. A., Kazi, H., Melo, H. M., McClean, P. L., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci57256 · Cited by 832
Insulin and neurodegenerative disease: shared and specific mechanisms
Craft, S., & Stennis Watson, G. (2004) · The Lancet Neurology · doi:10.1016/s1474-4422(04)00681-7 · Cited by 830
Intranasal insulin improves cognition and modulates β-amyloid in early AD
Reger, M. A., Watson, G. S., Green, P. S., Wilkinson, C. W., Baker, L. D., Cholerton, B., Fishel, M. A., Plymate, S. R., Breitner, J. C. S., DeGroodt, W., et al. (2008) · Neurology · doi:10.1212/01.wnl.0000265401.62434.36 · Cited by 830
Insulin-degrading Enzyme Regulates Extracellular Levels of Amyloid β-Protein by Degradation
Qiu, W. Q., Walsh, D. M., Ye, Z., Vekrellis, K., Zhang, J., Podlisny, M. B., Rosner, M. R., Safavi, A., Hersh, L. B., & Selkoe, D. J. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.49.32730 · Cited by 812
Moloney, A. M., Griffin, R. J., Timmons, S., O’Connor, R., Ravid, R., & O’Neill, C. (2010) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2008.04.002 · Cited by 764 · cited 4×
“…altered its distribution in AD neurons ↑ IGF-1R;↓IGFBP-2 ↑ IGF-1R surrounding and within plaques and in astrocytes ↓ IRS-1and IRS-2 protein levels ↑ phosphoIRS-1 levels near NFTs Moloney et al., 2010 AD human brain tissue/ cynomolgus monkeys (i.c.v. injection of Aβ oligomer/AβPP-PS1 Tg…”
BackgroundInfluentialBrain insulin and insulin receptors in aging and sporadic Alzheimer’s disease
Frölich, L., Blum-Degen, D., Bernstein, H.-G., Engelsberger, S., Humrich, J., Laufer, S., Muschner, D., Thalheimer, A., Türk, A., Hoyer, S., et al. (1998) · Journal of Neural Transmission · doi:10.1007/s007020050068 · Cited by 748
Rivera, E. J., Goldin, A., Fulmer, N., Tavares, R., Wands, J. R., & de la Monte, S. M. (2005) · Journal of Alzheimer s Disease · doi:10.3233/jad-2005-8304 · Cited by 723 · cited 5×
“AD etiology appears to be linked to a multitude of mechanisms that have not been yet completely elucidated.”
BackgroundInfluentialLeissring, M. A., Farris, W., Chang, A. Y., Walsh, D. M., Wu, X., Sun, X., Frosch, M. P., & Selkoe, D. J. (2003) · Neuron · doi:10.1016/s0896-6273(03)00787-6 · Cited by 719
Intranasal insulin improves memory in humans
Benedict, C., Hallschmid, M., Hatke, A., Schultes, B., Fehm, H. L., Born, J., & Kern, W. (2004) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2004.04.003 · Cited by 699 · cited 2×
“In a human study, the effects of 8 weeks of intranasal insulin (4 × 40 IU/d) and placebo were assessed on hippocampus-dependent declarative memory in 38 health subjects (Benedict et al., 2004).”
BackgroundMethodNew Perspectives into the Molecular Pathogenesis and Treatment of Type 2 Diabetes
Saltiel, A. R. (2001) · Cell · doi:10.1016/s0092-8674(01)00239-2 · Cited by 692
De Felice, F. G., Vieira, M. N. N., Bomfim, T. R., Decker, H., Velasco, P. T., Lambert, M. P., Viola, K. L., Zhao, W.-Q., Ferreira, S. T., & Klein, W. L. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0809158106 · Cited by 657 · cited 4×
“IR down-regulation and synaptic loss are markedly decreased by insulin treatment (de Felice et al., 2009).”
BackgroundResultInfluentialBaker, L. D., Cross, D. J., Minoshima, S., Belongia, D., Watson, G. S., & Craft, S. (2011) · Archives of Neurology · doi:10.1001/archneurol.2010.225 · Cited by 639 · cited 1×
“…of insulin resistance (Hoyer, 2002, 2004; Schubert et al., 2004; Rivera et al., 2005; Steen et al., 2005; Watson and Craft, 2006; Craft, 2007; Neumann et al., 2008; Krikorian et al., 2010; Luchsinger, 2010; Baker et al., 2011; Talbot et al., 2012; Butterfield et al., 2014a,b; de La Monte, 2014).”
BackgroundRole for neuronal insulin resistance in neurodegenerative diseases
Schubert, M., Gautam, D., Surjo, D., Ueki, K., Baudler, S., Schubert, D., Kondo, T., Alber, J., Galldiks, N., Küstermann, E., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0308724101 · Cited by 637
Insulin Action in Brain Regulates Systemic Metabolism and Brain Function
Kleinridders, A., Ferris, H. A., Cai, W., & Kahn, C. R. (2014) · Diabetes · doi:10.2337/db14-0568 · Cited by 625
Reger, M. A., Watson, G. S., Frey, W. H., Baker, L. D., Cholerton, B., Keeling, M. L., Belongia, D. A., Fishel, M. A., Plymate, S. R., Schellenberg, G. D., et al. (2006) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2005.03.016 · Cited by 621
Jiang, Z. Y., Lin, Y.-W., Clemont, A., Feener, E. P., Hein, K. D., Igarashi, M., Yamauchi, T., White, M. F., & King, G. L. (1999) · Journal of Clinical Investigation · doi:10.1172/jci5971 · Cited by 604 · cited 2×
“In insulin resistant state, there is a specific impairment in the vasodilatory PI3K pathway, whereas the Ras/MAPK-dependent pathway is unaffected (Jiang et al., 1999; Cusi et al., 2000).”
BackgroundAmyloid beta oligomers induce impairment of neuronal insulin receptors
Zhao, W., De Felice, F. G., Fernandez, S., Chen, H., Lambert, M. P., Quon, M. J., Krafft, G. A., & Klein, W. L. (2008) · The FASEB Journal · doi:10.1096/fj.06-7703com · Cited by 587 · cited 7×
“It has been demonstrated that, acute treatment with Aβ oligomer to hippocampus caused a rapid and substantial loss Frontiers in Neuroscience | www.frontiersin.org 5 June 2015 | Volume 9 | Article 204 of neuronal surface IRs specifically on dendrites bound (Zhao et al., 2008; de Felice et al., 2009).”
BackgroundInfluentialInsulin in the brain: There and back again
Banks, W. A., Owen, J. B., & Erickson, M. A. (2012) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2012.07.006 · Cited by 574
Craft, S., Peskind, E., Schwartz, M. W., Schellenberg, G. D., Raskind, M., & Porte, D. (1998) · Neurology · doi:10.1212/wnl.50.1.164 · Cited by 560
Memory improvement following induced hyperinsulinemia in Alzheimer’s disease
Craft, S., Newcomer, J., Kanne, S., Dagogo-Jack, S., Cryer, P., Sheline, Y., Luby, J., Dagogo-Jack, A., & Alderson, A. (1996) · Neurobiology of Aging · doi:10.1016/0197-4580(95)02002-0 · Cited by 538 · cited 2×
“Increasing brain insulin levels in AD patients by intravenous administration has been shown to acutely improve performance on hippocampus-dependent memory task (Craft et al., 1996).”
BackgroundMa, Q.-L., Yang, F., Rosario, E. R., Ubeda, O. J., Beech, W., Gant, D. J., Chen, P. P., Hudspeth, B., Chen, C., Zhao, Y., et al. (2009) · Journal of Neuroscience · doi:10.1523/jneurosci.1071-09.2009 · Cited by 536 · cited 14×
“Phosphorylation of IRS-1 (Ser 312 and 316) inhibits the regulation of insulin on GSK-3β activity, which leads to further increase in hyperphosphorylation of tau (Ma et al., 2009).”
BackgroundInfluentialInsulin and Insulin-like Growth Factor-1 Regulate Tau Phosphorylation in Cultured Human Neurons
Hong, M., & Lee, V. M.-Y. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.31.19547 · Cited by 522
Reger, M. A., Watson, G. S., Green, P. S., Baker, L. D., Cholerton, B., Fishel, M. A., Plymate, S. R., Cherrier, M. M., Schellenberg, G. D., Frey II, W. H., et al. (2008) · Journal of Alzheimer's Disease · doi:10.3233/jad-2008-13309 · Cited by 521
Deficient brain insulin signalling pathway in Alzheimer's disease and diabetes
Liu, Y., Liu, F., Grundke‐Iqbal, I., Iqbal, K., & Gong, C. (2011) · The Journal of Pathology · doi:10.1002/path.2912 · Cited by 502
Insulin and the insulin receptor in experimental models of learning and memory
Zhao, W.-Q., Chen, H., Quon, M. J., & Alkon, D. L. (2004) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2004.02.045 · Cited by 502
Vekrellis, K., Ye, Z., Qiu, W. Q., Walsh, D., Hartley, D., Chesneau, V., Rosner, M. R., & Selkoe, D. J. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-05-01657.2000 · Cited by 495
Insulin receptors and insulin action in the brain: review and clinical implications
Schulingkamp, R. J., Pagano, T. C., Hung, D., & Raffa, R. B. (2000) · Neuroscience & Biobehavioral Reviews · doi:10.1016/s0149-7634(00)00040-3 · Cited by 493
How does diabetes accelerate Alzheimer disease pathology?
Sims-Robinson, C., Kim, B., Rosko, A., & Feldman, E. L. (2010) · Nature Reviews Neurology · doi:10.1038/nrneurol.2010.130 · Cited by 492 · cited 1×
“In type 2 diabetes increased GSK-3β activity might lead to an elevation of Aβ production (Phiel et al., 2003) and increased tau phosphorylation (Freude et al., 2005; Sims-Robinson et al., 2010).”
BackgroundGasparini, L., Gouras, G. K., Wang, R., Gross, R. S., Beal, M. F., Greengard, P., & Xu, H. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-08-02561.2001 · Cited by 492
Insulin Receptor Substrate-2 Deficiency Impairs Brain Growth and Promotes Tau Phosphorylation
Schubert, M., Brazil, D. P., Burks, D. J., Kushner, J. A., Ye, J., Flint, C. L., Farhang-Fallah, J., Dikkes, P., Warot, X. M., Rio, C., et al. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-18-07084.2003 · Cited by 488
Craft, S. (2007) · Current Alzheimer Research · doi:10.2174/156720507780362137 · Cited by 487 · cited 1×
“…and worsening of insulin resistance (Hoyer, 2002, 2004; Schubert et al., 2004; Rivera et al., 2005; Steen et al., 2005; Watson and Craft, 2006; Craft, 2007; Neumann et al., 2008; Krikorian et al., 2010; Luchsinger, 2010; Baker et al., 2011; Talbot et al., 2012; Butterfield et al., 2014a,b; de…”
BackgroundDelivery of Neurotrophic Factors to the Central Nervous System: Pharmacokinetic Considerations
Thorne, R. G., & Frey, W. H. (2001) · Clinical Pharmacokinetics · doi:10.2165/00003088-200140120-00003 · Cited by 487
Dementia: a global health priority - highlights from an ADI and World Health Organization report
Wortmann, M. (2012) · Alzheimer's Research & Therapy · doi:10.1186/alzrt143 · Cited by 471
Freiherr, J., Hallschmid, M., Frey, W. H., Brünner, Y. F., Chapman, C. D., Hölscher, C., Craft, S., De Felice, F. G., & Benedict, C. (2013) · CNS Drugs · doi:10.1007/s40263-013-0076-8 · Cited by 468
Intracerebral streptozotocin model of type 3 diabetes: Relevance to sporadic Alzheimer’s disease
Lester-Coll, N., Rivera, E. J., Soscia, S. J., Doiron, K., Wands, J. R., & de la Monte, S. M. (2006) · Journal of Alzheimer s Disease · doi:10.3233/jad-2006-9102 · Cited by 467
Claxton, A., Baker, L. D., Hanson, A., Trittschuh, E. H., Cholerton, B., Morgan, A., Callaghan, M., Arbuckle, M., Behl, C., & Craft, S. (2015) · Journal of Alzheimer's Disease · doi:10.3233/jad-141791 · Cited by 467
Zeiher, A. M., Fisslthaler, B., Schray-Utz, B., & Busse, R. (1995) · Circulation Research · doi:10.1161/01.res.76.6.980 · Cited by 462
Brain Insulin Resistance and Deficiency as Therapeutic Targets in Alzheimers Disease
M. de la Monte, S. (2012) · Current Alzheimer Research · doi:10.2174/156720512799015037 · Cited by 448
Serum insulin-like growth factor I regulates brain amyloid-β levels
Carro, E., Trejo, J. L., Gomez-Isla, T., LeRoith, D., & Torres-Aleman, I. (2002) · Nature Medicine · doi:10.1038/nm793 · Cited by 448
Insulin signaling in the central nervous system: Learning to survive
van der Heide, L. P., Ramakers, G. M. J., & Smidt, M. P. (2006) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2006.06.003 · Cited by 444 · cited 2×
“Recent studies have demonstrated that insulin and insulin receptor (IR) are ubiquitously expressed in the brain as in peripheral tissues (Schulingkamp et al., 2000; Van Der Heide et al., 2006).”
BackgroundSerum insulin-like growth factor I regulates brain amyloid-β levels
Carro, E., Trejo, J. L., Gomez-Isla, T., LeRoith, D., & Torres-Aleman, I. (2002) · Nature Medicine · doi:10.1038/nm1202-793 · Cited by 440
Glucose metabolism and insulin receptor signal transduction in Alzheimer disease
Hoyer, S. (2004) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2004.02.049 · Cited by 434
Nitric Oxide Reversibly Inhibits the Migration of Cultured Vascular Smooth Muscle Cells
Sarkar, R., Meinberg, E. G., Stanley, J. C., Gordon, D., & Clinton Webb, R. (1996) · Circulation Research · doi:10.1161/01.res.78.2.225 · Cited by 421
Butterfield, D. A., Di Domenico, F., & Barone, E. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2014.06.010 · Cited by 402 · cited 2×
“…of insulin resistance (Hoyer, 2002, 2004; Schubert et al., 2004; Rivera et al., 2005; Steen et al., 2005; Watson and Craft, 2006; Craft, 2007; Neumann et al., 2008; Krikorian et al., 2010; Luchsinger, 2010; Baker et al., 2011; Talbot et al., 2012; Butterfield et al., 2014a,b; de La Monte, 2014).”
BackgroundWatson, G. S., & Craft, S. (2003) · CNS Drugs · doi:10.2165/00023210-200317010-00003 · Cited by 397
Gabuzda, D., Busciglio, J., Chen, L. B., Matsudaira, P., & Yankner, B. A. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)36875-8 · Cited by 373 · cited 1×
“Inhibition of energy metabolism can alter AβPP processing and induce amyloidogenic products (Gabuzda et al., 1994).”
BackgroundDefects of the insulin receptor substrate (IRS) system in human metabolic disorders
Sesti, G., Federici, M., Hribal, M. L., Lauro, D., Sbraccia, P., & Lauro, R. (2001) · The FASEB Journal · doi:10.1096/fj.01-0009rev · Cited by 353
Kurochkin, I. V., & Goto, S. (1994) · FEBS Letters · doi:10.1016/0014-5793(94)00387-4 · Cited by 340
Alzheimer’s disease and insulin resistance: translating basic science into clinical applications
De Felice, F. G. (2013) · Journal of Clinical Investigation · doi:10.1172/jci64595 · Cited by 330
Zhao, L., Teter, B., Morihara, T., Lim, G. P., Ambegaokar, S. S., Ubeda, O. J., Frautschy, S. A., & Cole, G. M. (2004) · The Journal of Neuroscience · doi:10.1523/jneurosci.2860-04.2004 · Cited by 329
Insulin in Central Nervous System: More than Just a Peripheral Hormone
Duarte, A. I., Moreira, P. I., & Oliveira, C. R. (2012) · Journal of Aging Research · doi:10.1155/2012/384017 · Cited by 322
Potenza, M. A., Marasciulo, F. L., Chieppa, D. M., Brigiani, G. S., Formoso, G., Quon, M. J., & Montagnani, M. (2005) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00092.2005 · Cited by 314 · cited 1×
“Activation of MAPK stimulates release of endothelin-1 (ET1), a vasoconstrictor (Figure 1A) (Potenza et al., 2005, 2006; Formoso et al., 2006).”
BackgroundDoes insulin dysfunction play a role in Alzheimer's disease?
Gasparini, L. (2002) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(02)02037-0 · Cited by 314
Chung, H. J., Huang, Y. H., Lau, L.-F., & Huganir, R. L. (2004) · The Journal of Neuroscience · doi:10.1523/jneurosci.0546-04.2004 · Cited by 313
Type 3 diabetes is sporadic Alzheimer׳s disease: Mini-review
de la Monte, S. M. (2014) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2014.06.008 · Cited by 313
Intranasal Insulin Improves Memory in Humans: Superiority of Insulin Aspart
Benedict, C., Hallschmid, M., Schmitz, K., Schultes, B., Ratter, F., Fehm, H. L., Born, J., & Kern, W. (2007) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301193 · Cited by 302 · cited 3×
“The same research group further studied effects of rapid-acting insulin analog insulin aspart, regular human insulin and placebo under similar experimental conditions (Benedict et al., 2007).”
BackgroundInfluentialBenedict, C., Kern, W., Schultes, B., Born, J., & Hallschmid, M. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-2606 · Cited by 296 · cited 2×
“…insulin 160 IU Hippocampus-dependent memory and working memory were improved in women where as men did not benefit from acute insulin treatment Benedict et al., 2008; Krug et al., 2010 MCI and mild AD patients 20 or 40 IU of insulin acute treatment Acute intranasal insulin administration…”
BackgroundMethodChen, Y., Liang, Z., Blanchard, J., Dai, C.-L., Sun, S., Lee, M. H., Grundke-Iqbal, I., Iqbal, K., Liu, F., & Gong, C.-X. (2013) · Molecular Neurobiology · doi:10.1007/s12035-012-8375-5 · Cited by 288
de la Monte, S. M. (2012) · Drugs · doi:10.2165/11597760-000000000-00000 · Cited by 265 · cited 3×
“It is now proposed that impairments in brain insulin/IGF signaling is associated with increased accumulation of Aβ, phosphorylated tau, reactive oxygen/nitrogen species, pro-inflammatory and pro-apoptosis molecules (de La Monte et al., 2009; de La Monte, 2012a,b, 2014).”
BackgroundInsulin increases CSF Aβ42 levels in normal older adults
Watson, G. S., Peskind, E. R., Asthana, S., Purganan, K., Wait, C., Chapman, D., Schwartz, M. W., Plymate, S., & Craft, S. (2003) · Neurology · doi:10.1212/01.wnl.0000065916.25128.25 · Cited by 264
Pérez, A., Morelli, L., Cresto, J. C., & Castaño, E. M. (2000) · Neurochemical Research · doi:10.1023/a:1007527721160 · Cited by 240
Fuenzalida, K., Quintanilla, R., Ramos, P., Piderit, D., Fuentealba, R. A., Martinez, G., Inestrosa, N. C., & Bronfman, M. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m700447200 · Cited by 237
Insulin Resistance and Alzheimers Disease: Molecular Links & Clinical Implications
Neumann, K., Rojo, L., Navarrete, L., Farias, G., Reyes, P., & Maccioni, R. (2008) · Current Alzheimer Research · doi:10.2174/156720508785908919 · Cited by 236 · cited 1×
“…of insulin resistance (Hoyer, 2002, 2004; Schubert et al., 2004; Rivera et al., 2005; Steen et al., 2005; Watson and Craft, 2006; Craft, 2007; Neumann et al., 2008; Krikorian et al., 2010; Luchsinger, 2010; Baker et al., 2011; Talbot et al., 2012; Butterfield et al., 2014a,b; de La Monte,…”
BackgroundDeng, Y., Li, B., Liu, Y., Iqbal, K., Grundke-Iqbal, I., & Gong, C.-X. (2009) · The American Journal of Pathology · doi:10.2353/ajpath.2009.090157 · Cited by 233
Growth hormone, insulin-like growth factor-1 and the aging brain
Ashpole, N. M., Sanders, J. E., Hodges, E. L., Yan, H., & Sonntag, W. E. (2015) · Experimental Gerontology · doi:10.1016/j.exger.2014.10.002 · Cited by 225
Yarchoan, M., Toledo, J. B., Lee, E. B., Arvanitakis, Z., Kazi, H., Han, L.-Y., Louneva, N., Lee, V. M.-Y., Kim, S. F., Trojanowski, J. Q., et al. (2014) · Acta Neuropathologica · doi:10.1007/s00401-014-1328-5 · Cited by 207
The brain insulin signal transduction system and sporadic (type II) Alzheimer disease: an update
Hoyer, S. (2002) · Journal of Neural Transmission · doi:10.1007/s007020200028 · Cited by 205
de la Monte, S. M., Longato, L., Tong, M., & Wands, J. R. (2009) · PubMed · Cited by 192
Stockhorst, U., de Fries, D., Steingrueber, H.-J., & Scherbaum, W. A. (2004) · Physiology & Behavior · doi:10.1016/j.physbeh.2004.07.022 · Cited by 192
An Integrative View of the Role of Oxidative Stress, Mitochondria and Insulin in Alzheimer's Disease
Moreira, P. I., Duarte, A. I., Santos, M. S., Rego, A. C., & Oliveira, C. R. (2009) · Journal of Alzheimer's Disease · doi:10.3233/jad-2009-0972 · Cited by 190
Solano, D. C., Sironi, M., Bonfini, C., Solerte, S. B., Govoni, S., & Racchi, M. (2000) · The FASEB Journal · doi:10.1096/fasebj.14.7.1015 · Cited by 177
Authier, F., Posner, B. I., & Bergeron, J. J. M. (1996) · PubMed · Cited by 165
Insulin-like growth factor-I, cognition and brain aging
van Dam, P. S., & Aleman, A. (2004) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2004.02.047 · Cited by 163
Intranasal insulin as a therapeutic option in the treatment of cognitive impairments
Benedict, C., Frey, W. H., Schiöth, H. B., Schultes, B., Born, J., & Hallschmid, M. (2011) · Experimental Gerontology · doi:10.1016/j.exger.2010.08.026 · Cited by 159
Wang, X., Zheng, W., Xie, J.-W., Wang, T., Wang, S.-L., Teng, W.-P., & Wang, Z.-Y. (2010) · Molecular Neurodegeneration · doi:10.1186/1750-1326-5-46 · Cited by 159
Hypertriglyceridemia and Hyperinsulinemia Are Potent Inducers of Endothelin-1 Release in Humans
Piatti, P., Monti, L. D., Conti, M., Baruffaldi, L., Galli, L., Phan, C. V., Guazzini, B., Pontiroli, A. E., & Pozza, G. (1996) · Diabetes · doi:10.2337/diab.45.3.316 · Cited by 157
Neuropathological role of PI3K/Akt/mTOR axis in Down syndrome brain
Perluigi, M., Pupo, G., Tramutola, A., Cini, C., Coccia, R., Barone, E., Head, E., Butterfield, D. A., & Di Domenico, F. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2014.04.007 · Cited by 155 · cited 1×
“Akt inactivates GSK-3β, which inhibits tau phosphorylation (Zhao et al., 2009; Perluigi et al., 2014).”
BackgroundTham, A., Nordberg, A. K., Grissom, F. E., Carlsson‐Skwirut, C., Viitanen, M. H., & Sara, V. R. (1993) · Journal of Neural Transmission - Parkinsons Disease and Dementia Section · doi:10.1007/bf02257671 · Cited by 155
Insulin Receptor Dysfunction Impairs Cellular Clearance of Neurotoxic Oligomeric Aβ
Zhao, W.-Q., Lacor, P. N., Chen, H., Lambert, M. P., Quon, M. J., Krafft, G. A., & Klein, W. L. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.011015 · Cited by 154
Functions of PI 3‐kinase in development of the nervous system
Rodgers, E. E., & Theibert, A. B. (2002) · International Journal of Developmental Neuroscience · doi:10.1016/s0736-5748(02)00047-3 · Cited by 154
Amyloid β protein precursor and the pathogenesis of Alzheimer's disease
Selkoe, D. J. (1989) · Cell · doi:10.1016/0092-8674(89)90093-7 · Cited by 154
Molecular genetics of Alzheimer's disease
Cruts, M., & vanBroeckhoven, C. (1998) · Annals of Medicine · doi:10.3109/07853899809002605 · Cited by 148
Peripheral Hyperinsulinemia Promotes Tau Phosphorylation In Vivo
Freude, S., Plum, L., Schnitker, J., Leeser, U., Udelhoven, M., Krone, W., Bruning, J. C., & Schubert, M. (2005) · Diabetes · doi:10.2337/diabetes.54.12.3343 · Cited by 144
Doré, S., Kar, S., Rowe, W. B., & Quirion, R. (1997) · Neuroscience · doi:10.1016/s0306-4522(97)00154-1 · Cited by 141
Tau Therapeutic Strategies for the Treatment of Alzheimers Disease
Churcher, I. (2006) · Current Topics in Medicinal Chemistry · doi:10.2174/156802606776743057 · Cited by 141
The role of caspases in Alzheimer’s disease; potential novel therapeutic opportunities
Rohn, T. T. (2010) · APOPTOSIS · doi:10.1007/s10495-010-0463-2 · Cited by 133
Chen, Y., Yang, Z., Dai, C., Liang, Z., Run, X., Iqbal, K., Liu, F., & Gong, C. (2014) · Experimental Neurology · doi:10.1016/j.expneurol.2014.06.004 · Cited by 132
Lesort, M. J., & Johnson, G. V. W. (2000) · Neuroscience · doi:10.1016/s0306-4522(00)00200-1 · Cited by 129
Fujisawa, Y., Sasaki, K., & Akiyama, K. (1991) · Biological Psychiatry · doi:10.1016/0006-3223(91)90158-i · Cited by 123
Watson, G. S., & Craft, S. (2006) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2005.08.017 · Cited by 121
Intranasal Insulin Ameliorates Tau Hyperphosphorylation in a Rat Model of Type 2 Diabetes
Yang, Y., Ma, D., Wang, Y., Jiang, T., Hu, S., Zhang, M., Yu, X., & Gong, C.-X. (2012) · Journal of Alzheimer's Disease · doi:10.3233/jad-2012-121294 · Cited by 120
Mass spectrometry and redox proteomics: Applications in disease
Butterfield, D. A., Gu, L., Domenico, F. D., & Robinson, R. A. S. (2014) · Mass Spectrometry Reviews · doi:10.1002/mas.21374 · Cited by 115
Wang, Y. L., Frauwirth, K. A., Rangwala, S. M., Lazar, M. A., & Thompson, C. B. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m204279200 · Cited by 113
de la Monte, S. M. (2012) · Journal of Alzheimer s Disease · doi:10.3233/jad-2012-111727 · Cited by 109
Insulin signaling leading to proliferation, survival, and membrane ruffling in C2C12 myoblasts
Conejo, R., & Lorenzo, M. (2001) · Journal of Cellular Physiology · doi:10.1002/1097-4652(2001)9999:9999<::aid-jcp1058>3.0.co;2-v · Cited by 108
Formoso, G., Chen, H., Kim, J.-A., Montagnani, M., Consoli, A., & Quon, M. J. (2006) · Molecular Endocrinology · doi:10.1210/me.2005-0266 · Cited by 103
Bedse, G., Romano, A., Lavecchia, A. M., Cassano, T., & Gaetani, S. (2014) · Journal of Alzheimer’s Disease · doi:10.3233/jad-141635 · Cited by 102
Self-citationHölscher, C., & Li, L. (2008) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2008.08.023 · Cited by 100
New Twist on Neuronal Insulin Receptor Signaling in Health, Disease, and Therapeutics
Wada, A., Yokoo, H., Yanagita, T., & Kobayashi, H. (2005) · Journal of Pharmacological Sciences · doi:10.1254/jphs.crj05006x · Cited by 96
Reduced brain insulin-like growth factor I function during aging
Muller, A. P., Fernandez, A. M., Haas, C. B., Zimmer, E. R., Portela, L. V., & Torres‐Alemán, I. (2011) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2011.07.008 · Cited by 93
Tau Is Hyperphosphorylated in the Insulin-Like Growth Factor-I Null Brain
Cheng, C. M., Tseng, V., Wang, J., Wang, D., Matyakhina, L., & Bondy, C. A. (2005) · Endocrinology · doi:10.1210/en.2005-0063 · Cited by 92
Type 2 diabetes, related conditions, in relation and dementia: An opportunity for prevention?
Luchsinger, J. A. (2010) · Journal of Alzheimer s Disease · doi:10.3233/jad-2010-091687 · Cited by 91 · cited 2×
“…of insulin resistance (Hoyer, 2002, 2004; Schubert et al., 2004; Rivera et al., 2005; Steen et al., 2005; Watson and Craft, 2006; Craft, 2007; Neumann et al., 2008; Krikorian et al., 2010; Luchsinger, 2010; Baker et al., 2011; Talbot et al., 2012; Butterfield et al., 2014a,b; de La Monte, 2014).”
BackgroundIncreased Circulating Insulin-like Growth Factor-1 in Late-onset Alzheimer's Disease
Vardy, E. R. L. C., Rice, P. J., Bowie, P. C. W., Holmes, J. D., Grant, P. J., & Hooper, N. M. (2007) · Journal of Alzheimer's Disease · doi:10.3233/jad-2007-12401 · Cited by 91
Deregulation of brain insulin signaling in Alzheimer’s disease
Chen, Y., Deng, Y., Zhang, B., & Gong, C. (2014) · Neuroscience Bulletin · doi:10.1007/s12264-013-1408-x · Cited by 90
Mustafa, A., Lannfelt, L., Lilius, L., Islam, A., Winblad, B. G., & Adem, A. (1999) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000017188 · Cited by 86
Brodbeck, J., Balestra, M. E., Saunders, A. M., Roses, A. D., Mahley, R. W., & Huang, Y. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0709906104 · Cited by 86
Potenza, M. A., Marasciulo, F. L., Tarquinio, M., Quon, M. J., & Montagnani, M. (2006) · Diabetes · doi:10.2337/db06-0667 · Cited by 86
Insulin Levels are Decreased in the Cerebrospinal Fluid of Women with Prodomal Alzheimer's Disease
Gil-Bea, F. J., Solas, M., Solomon, A., Mugueta, C., Winblad, B., Kivipelto, M., Ramirez, M. J., & Cedazo-Mínguez, A. (2010) · Journal of Alzheimer's Disease · doi:10.3233/jad-2010-100795 · Cited by 79
Improved cognitive-cerebral function in older adults with chromium supplementation
Krikorian, R., Eliassen, J. C., Boespflug, E. L., Nash, T. A., & Shidler, M. D. (2010) · Nutritional Neuroscience · doi:10.1179/147683010x12611460764084 · Cited by 74
Krug, R., Benedict, C., Born, J., & Hallschmid, M. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-0744 · Cited by 74
Sudoh, S., Frosch, M. P., & Wolf, B. A. (2002) · Biochemistry · doi:10.1021/bi011193l · Cited by 73
Son, S. M., Song, H., Byun, J., Park, K. S., Jang, H. C., Park, Y. J., & Mook-Jung, I. (2012) · Diabetes · doi:10.2337/db11-1735 · Cited by 72
Salehi, Z., Mashayekhi, F., & Naji, M. (2008) · BioFactors · doi:10.1002/biof.5520330202 · Cited by 71
Rosenbloom, M. H., Barclay, T. R., Pyle, M., Owens, B. L., Cagan, A., Anderson, C. P., Frey, W. H., & Hanson, L. R. (2014) · CNS Drugs · doi:10.1007/s40263-014-0214-y · Cited by 66
Rajasekar, N., Dwivedi, S., Nath, C., Hanif, K., & Shukla, R. (2014) · Neuropharmacology · doi:10.1016/j.neuropharm.2014.08.013 · Cited by 61
Hallschmid, M., Schultes, B., Marshall, L., Mölle, M., Kern, W., Bredthauer, J., Fehm, H. L., & Born, J. (2004) · Diabetes · doi:10.2337/diabetes.53.9.2202 · Cited by 50
Intranasal insulin prevents anesthesia-induced hyperphosphorylation of tau in 3xTg-AD mice
Chen, Y., Run, X., Liang, Z., Zhao, Y., Dai, C., Iqbal, K., Liu, F., & Gong, C. (2014) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2014.00100 · Cited by 49
Yamamoto, N., Matsubara, T., Sobue, K., Tanida, M., Kasahara, R., Naruse, K., Taniura, H., Sato, T., & Suzuki, K. (2012) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2012.07668.x · Cited by 48
Kar, S., Poirier, J., Guevara, J., Dea, D., Hawkes, C. A., Robitaille, Y., & Quirion, R. (2005) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2005.03.005 · Cited by 46
Kahn, A. M., Husid, A., Allen, J. C., Seidel, C. L., & Song, T. (1997) · Hypertension · doi:10.1161/01.hyp.30.4.928 · Cited by 41
Colbert, L. H., Rosen, C. J., Goodpaster, B. H., Newman, A. B., Kritchevsky, S. B., Satterfield, S., Kanaya, A. M., Taaffe, D. R., & Harris, T. B. (2004) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2004.52529_1.x · Cited by 39
US government sets out Alzheimer’s plan
Wadman, M. (2012) · Nature · doi:10.1038/485426a · Cited by 32
Understanding Alzheimer's Disease
Zerr, I. (2013) · InTech eBooks · doi:10.5772/46004 · Cited by 32
Intranasal administration of insulin lowers amyloid-beta levels in rat model of diabetes.
Subramanian, S., & John, M. (2012) · PubMed · Cited by 27
Insulin and Insulin-Like Growth Factor I
Zapf, J., Scheiwiller, E., Guler, H. P., & Froesch, E. R. (1987) · Endocrinologia Japonica · doi:10.1507/endocrj1954.34.supplement_123 · Cited by 26
Alzheimer’s Disease and Diabetes
Brent, D. A., Gary, L., Aboud, Z., & Gordon, W. (2013) · InTech eBooks · doi:10.5772/54913 · Cited by 8
Cited by
Healthy Effects of Plant Polyphenols: Molecular Mechanisms
Leri, M., Scuto, M., Ontario, M. L., Calabrese, V., Calabrese, E. J., Bucciantini, M., & Stefani, M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21041250 · Cited by 435
The amyloid cascade hypothesis: are we poised for success or failure?
Karran, E., & De Strooper, B. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13632 · Cited by 402
“clinical experiments where insulin has been intranasally delivered directly into the brain with promising results (Craft et al. 2012; Bedse et al. 2015), leading to a much larger”
BackgroundType 3 Diabetes and Its Role Implications in Alzheimer’s Disease
Nguyen, T. T., Ta, Q. T. H., Nguyen, T. K. O., Nguyen, T. T. D., & Van Giau, V. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21093165 · Cited by 393
Rigacci, S., & Stefani, M. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17060843 · Cited by 290
Perluigi, M., Di Domenico, F., & Butterfield, D. A. (2024) · Physiological Reviews · doi:10.1152/physrev.00030.2022 · Cited by 282
Self-citation
Metadata
- Authors
- Bedse, G., Di Domenico, F., Serviddio, G., & Cassano, T.
- Venue
- Frontiers in Neuroscience
- Publisher
- Frontiers Media SA
- Published
- 2015-06-16
- Volume
- 9
- Pages
- 204-204
- ISSN
- 1662-453X (ISSN-L)
- OpenAlex
- W1526704928
- Cited by
- 292
- References
- 145
- FWCI
- 21.31
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.